Therapeutic Targeting of Neuroinflammation in Methamphetamine Use Disorder

Overview

Journal Future Med Chem

Specialties Chemistry
Pharmacy

Date 2024 Dec 27

PMID 39727147

Authors

Natasha Jeffery

Phooi Yan Mock

Kun Yang

Chau Ling Tham

Daud Ahmad Israf

Hongyuan Li

Xiaohui Wang

Kok Wai Lam

Affiliations

Soon will be listed here.

Abstract

Methamphetamine (METH) is a highly addictive illicit psychostimulant with a significant annual fatality rate. Emerging studies highlight its role in neuroinflammation and a range of neurological disorders. This review examines the current landscape of potential drug targets for managing neuroinflammation in METH use disorders (MUDs), with a particular focus on the rationale behind targeting Toll-like receptor 4 (TLR4), the NLR family pyrin domain containing 3 (NLRP3) inflammasome, and other promising targets. Given the multifactorial neurological effects of METH, including cognitive impairment and neurodegeneration, addressing METH-induced neuroinflammation has shown considerable promise in partially mitigating the damaging effects on the central nervous system and improving behavioral outcomes. This article provides an overview of the existing understanding while charting a promising path forward for developing innovative MUD treatments, focusing on neuroinflammation as a therapeutic target. Targeting neuroinflammation in METH-induced neurological disorders shows significant promise in mitigating cognitive impairment and neurodegeneration, offering a potential therapeutic strategy for improving outcomes in MUD. While challenges remain in optimizing treatments, ongoing research into combination therapies, novel drug delivery systems, and neuroprotective agents suggests a positive outlook for more effective interventions.

References

Moratalla R, Khairnar A, Simola N, Granado N, Garcia-Montes J, Porceddu P . Amphetamine-related drugs neurotoxicity in humans and in experimental animals: Main mechanisms. Prog Neurobiol. 2015; 155:149-170. DOI: 10.1016/j.pneurobio.2015.09.011. View

Xu E, Liu J, Liu H, Wang X, Xiong H . Role of microglia in methamphetamine-induced neurotoxicity. Int J Physiol Pathophysiol Pharmacol. 2017; 9(3):84-100. PMC: 5498881. View

Northoff G . The brain's spontaneous activity and its psychopathological symptoms - "Spatiotemporal binding and integration". Prog Neuropsychopharmacol Biol Psychiatry. 2017; 80(Pt B):81-90. DOI: 10.1016/j.pnpbp.2017.03.019. View

Burgess A, Shah K, Hough O, Hynynen K . Focused ultrasound-mediated drug delivery through the blood-brain barrier. Expert Rev Neurother. 2015; 15(5):477-91. PMC: 4702264. DOI: 10.1586/14737175.2015.1028369. View

Takahashi O, Ohashi N, Nakae D, Ogata A . Parenteral paradichlorobenzene exposure reduces sperm production, alters sperm morphology and exhibits an androgenic effect in rats and mice. Food Chem Toxicol. 2010; 49(1):49-56. DOI: 10.1016/j.fct.2010.09.029. View

Sofroniew M, Vinters H . Astrocytes: biology and pathology. Acta Neuropathol. 2009; 119(1):7-35. PMC: 2799634. DOI: 10.1007/s00401-009-0619-8. View

Knollmann B, Casimiro M, Katchman A, Sirenko S, Schober T, Rong Q . Isoproterenol exacerbates a long QT phenotype in Kcnq1-deficient neonatal mice: possible roles for human-like Kcnq1 isoform 1 and slow delayed rectifier K+ current. J Pharmacol Exp Ther. 2004; 310(1):311-8. DOI: 10.1124/jpet.103.063743. View

Shearer J, Darke S, Rodgers C, Slade T, van Beek I, Lewis J . A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence. Addiction. 2009; 104(2):224-33. DOI: 10.1111/j.1360-0443.2008.02437.x. View

Zhang P, Haidet-Phillips A, Pham J, Lee Y, Huo Y, Tienari P . Generation of GFAP::GFP astrocyte reporter lines from human adult fibroblast-derived iPS cells using zinc-finger nuclease technology. Glia. 2015; 64(1):63-75. PMC: 4715664. DOI: 10.1002/glia.22903. View

Thomas D, Walker P, Benjamins J, Geddes T, Kuhn D . Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation. J Pharmacol Exp Ther. 2004; 311(1):1-7. DOI: 10.1124/jpet.104.070961. View

Gundlach A, Largent B, Snyder S . Autoradiographic localization of sigma receptor binding sites in guinea pig and rat central nervous system with (+)3H-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine. J Neurosci. 1986; 6(6):1757-70. PMC: 6568729. View

Brinkley-Rubinstein L, Macmadu A, Marshall B, Heise A, Ranapurwala S, Rich J . Risk of fentanyl-involved overdose among those with past year incarceration: Findings from a recent outbreak in 2014 and 2015. Drug Alcohol Depend. 2018; 185:189-191. DOI: 10.1016/j.drugalcdep.2017.12.014. View

Martins T, Baptista S, Goncalves J, Leal E, Milhazes N, Borges F . Methamphetamine transiently increases the blood-brain barrier permeability in the hippocampus: role of tight junction proteins and matrix metalloproteinase-9. Brain Res. 2011; 1411:28-40. DOI: 10.1016/j.brainres.2011.07.013. View

Billnitzer A, Barskaya I, Yin C, Perez R . APP independent and dependent effects on neurite outgrowth are modulated by the receptor associated protein (RAP). J Neurochem. 2012; 124(1):123-32. PMC: 3800135. DOI: 10.1111/jnc.12051. View

de Iaco A, Luban J . Cyclophilin A promotes HIV-1 reverse transcription but its effect on transduction correlates best with its effect on nuclear entry of viral cDNA. Retrovirology. 2014; 11:11. PMC: 3916700. DOI: 10.1186/1742-4690-11-11. View

Minozzi S, Saulle R, De Crescenzo F, Amato L . Psychosocial interventions for psychostimulant misuse. Cochrane Database Syst Rev. 2016; 9:CD011866. PMC: 6457581. DOI: 10.1002/14651858.CD011866.pub2. View

10.

Stoops W, Rush C . Combination pharmacotherapies for stimulant use disorder: a review of clinical findings and recommendations for future research. Expert Rev Clin Pharmacol. 2014; 7(3):363-74. PMC: 4017926. DOI: 10.1586/17512433.2014.909283. View

11.

Bowyer J, Ali S . High doses of methamphetamine that cause disruption of the blood-brain barrier in limbic regions produce extensive neuronal degeneration in mouse hippocampus. Synapse. 2006; 60(7):521-32. DOI: 10.1002/syn.20324. View

12.

Rambousek L, Bubenikova-Valesova V, Kacer P, Syslova K, Kenney J, Holubova K . Cellular and behavioural effects of a new steroidal inhibitor of the N-methyl-d-aspartate receptor 3α5β-pregnanolone glutamate. Neuropharmacology. 2011; 61(1-2):61-8. DOI: 10.1016/j.neuropharm.2011.02.018. View

12.

Shah A, Silverstein P, Singh D, Kumar A . Involvement of metabotropic glutamate receptor 5, AKT/PI3K signaling and NF-κB pathway in methamphetamine-mediated increase in IL-6 and IL-8 expression in astrocytes. J Neuroinflammation. 2012; 9:52. PMC: 3338363. DOI: 10.1186/1742-2094-9-52. View